A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 20 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2018.
- 24 May 2016 Status changed from not yet recruiting to recruiting.